Epetraborole在脓肿分枝杆菌肺病中空纤维模型的临床前评价
在脓肿分枝杆菌肺病空纤维模型中,Epetraborole对59株临床分离株的MIC50为0.125 mg/L、MIC90为0.25 mg/L;其最大杀菌效果比第0天负荷低253 cfu/mL,优于其他受试药物,但杀菌作用因耐药突变而终止,且呈暴露依赖性。蒙特卡洛模拟显示750 mg每日两次静脉给药有95.6%虚拟患者达到EC80。
要点
- Epetraborole在HFS-MAB中杀菌效果为目前最佳,优于奥马环素。
- 耐药突变随暴露浓度出现,包括Asp433Val、Arg324Ser、Phe310Cys。
- EC80对应AUC0-24/MIC=202.73,750 mg每日两次静脉给药达标率高。
核心结论
- Epetraborole在HFS-MAB中杀菌效果优于其他受试药物,但耐药突变限制其作用。
- 建议先于HFS-MAB中测试Epetraborole联合奥马环素及β-内酰胺方案,再开展临床试验。
研究设计与样本
- 临床前研究,检测Epetraborole对59株脓肿分枝杆菌分离株的MIC。
- 在HFS-MAB中测试7种Epetraborole暴露方案,持续21天。
- 采用抑制型S型Emax模型分析杀菌,二次函数分析耐药,蒙特卡洛实验确定最佳剂量。
主要发现
- Epetraborole的MIC50为0.125 mg/L,MIC90为0.25 mg/L。
- Epetraborole最大杀菌低于第0天负荷253 cfu/mL,而GBT为17 cfu/mL、阿米卡星为3 cfu/mL、亚胺培南为20 cfu/mL、替加环素为24 cfu/mL。
- Epetraborole杀菌效果是奥马环素(123 cfu/mL)的两倍以上。
- 全基因组测序显示浓度依赖性产生LeuRS耐药突变,包括Asp433Val、Arg324Ser、Phe310Cys。
- EC80对应AUC0-24/MIC=202.73;蒙特卡洛实验中750 mg每日两次静脉给药95.6%虚拟患者达标,口服为79.2%。
关键数值与推荐
- Epetraborole MIC50 0.125 mg/L,MIC90 0.25 mg/L(59株脓肿分枝杆菌)。
- EC80为AUC0-24/MIC=202.73。
- 750 mg每日两次静脉给药达标率95.6%,口服79.2%(虚拟患者)。
临床怎么用
- 提示Epetraborole可能作为脓肿分枝杆菌肺病联合方案的候选药物。
- 推荐先于HFS-MAB中评估Epetraborole+奥马环素+β-内酰胺联合方案,再进入临床试验。
局限性
- 研究为临床前空纤维模型,非人体试验。
- Epetraborole单药杀菌作用因耐药突变而终止。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In patients with Mycobacterium abscessus (MAB) lung disease (LD), guideline-based therapy (GBT) achieves sputum culture conversion in only 20-35% of patients. The poor efficacy is reflected in the hollow fibre model system for MAB-LD (HFS-MAB), where GBT drugs' maximal microbial kill (Emax) below day 0 burden (B0) were amikacin 3 colony-forming units (cfu)/mL, clarithromycin-cefoxitin-amikacin (GBT) 17 cfu/mL, imipenem 20 cfu/mL, and tigecycline 24 cfu/mL. METHODS: We tested the bacterial leucyl-tRNA synthetase (LeuRS) inhibitor, epetraborole, for MICs in 59 MAB isolates, and with seven epetraborole exposures in the HFS-MAB over 21 days. Data were analysed using the inhibitory sigmoid Emax model for microbial kill, and a quadratic function for resistance. Monte Carlo experiments (MCE) were performed to identify the optimal epetraborole dose for the clinic. RESULTS: The epetraborole MIC50 was 0.125 mg/L, and the MIC90 was 0.25 mg/L. Epetraborole killed 253 cfu/mL below B0. However, epetraborole microbial effect was terminated by antimicrobial resistance, in an exposure-dependent fashion. Whole genome sequencing revealed concentration-dependent generation of resistance-associated LeuRS mutations, including novel mutations such as Asp433Val, Arg324Ser, and Phe310Cys. The exposure mediating 80% of Emax (EC80) was an AUC0-24/MIC = 202.73. In MCE 750 mg twice daily achieved EC80 in 95.6% and 79.2% of virtual patients for intravenous versus oral administration, respectively. CONCLUSION: Epetraborole microbial kill is the best, thus far, achieved in the HFS-MAB, more than two times omadacycline's 123 cfu/mL below B0. We propose to test a novel combination regimen of epetraborole plus omadacycline plus a β-lactam versus GBT first in the HFS-MAB, followed by clinical trials.
引用
- Singh S, Boorgula GD, Nguyen MH, et al. Preclinical evaluation of epetraborole in the hollow fibre system model of Mycobacterium abscessus lung disease. J Antimicrob Chemother. 2026. PMID: 41191958. doi:10.1093/jac/dkaf405
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。